In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed.

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new assay measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

For healthcare professionals seeking to enhance their understanding of the assessment and treatment options for patients with neurodegenerative diseases.

PACE/State of FL - PRESENTATION RECORDING COMING SOON - Negotiating, maintaining and monitoring payer agreements.

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial therapies.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT).

PACE/State of FL - The role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer.

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

In this microlearning, we'll explore the importance of human connection in our daily lives and how the sense of belonging is a fundamental part of being human. As technology evolves, it reshapes how we interact with one another, creating new ways to connect and communicate, even in the realm of human relationships.

A compilation of interviews from previous episodes highlighting the pivotal role laboratory professionals play in healthcare. Featured interviews include Dr. Eric Hsi, Dr. Curt Hanson, and Jane Hermanson, all from Mayo Clinic in Rochester, Minnesota.

Due to severe weather affecting the FedEx hub in Memphis, Tennessee, delays are anticipated. The Mayo Clinic Laboratories’ Global Logistics team will be diverting work to other commercial shipping options.  

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.

Mayo Clinic Laboratories Education is pleased to announce the release of six new phlebotomy learning modules, which encompass many of the necessary skills to further your journey as a phlebotomist.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by colleagues Ellen Dijkman Dulkes and Brianne Newton. They build on their previous discussion about customer service by focusing on service recovery. They discuss strategies for responding to mishaps in the laboratory in a way that supports your broader customer service goals.